- Home
- PRME
PRME
Prime Medicine Inc.
as 07-26-2024 4:00pm EST
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 629.0M | IPO Year: | 2022 |
| Target Price: | $15.70 | AVG Volume (30 days): | 902.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.11 - $15.75 | Next Earning Date: | 08-05-2024 |
| Revenue: | $591,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -8.90% |
Stock Insider Trading Activity of Prime Medicine Inc. (PRME)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ARCH Venture Partners X, LLC | PRME | 10% Owner | Feb 15 '24 | Buy | $6.25 | 3,200,000 | $20,000,000.00 | 3,200,000 | SEC Form 4 |
| ARCH Venture Partners XII, LLC | PRME | 10% Owner | Feb 15 '24 | Buy | $6.25 | 3,200,000 | $20,000,000.00 | 3,200,000 | SEC Form 4 |
| NELSEN ROBERT | PRME | Director10% Owner | Feb 15 '24 | Buy | $6.25 | 3,200,000 | $20,000,000.00 | 3,200,000 | SEC Form 4 |
Latest Prime Medicine Inc. News
PRME Breaking Stock News: Dive into PRME Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
Insider Monkey
18 days ago
Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now?
Zacks
a month ago
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks
2 months ago
Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade
GlobeNewswire
2 months ago
Prime Medicine to Present at Upcoming Investor Conferences
Motley Fool
2 months ago
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
TipRanks
2 months ago
Cathie Wood Pulls the Trigger on These 2 ‘Strong Buy’ Stocks
MT Newswires
2 months ago
HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target
Compare PRME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRME Prime Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.